Novo Nordisk's GLP-1 Market Growth (Novo Nordisk's Q1-2025 Investor Presentation) The next risk is drug pricing reform in the US, as it could pressure margins.

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to ...

Key Points Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is ...

The Danish government and the foundation behind Novo Nordisk A/S will invest €80 million ($93 million) in a Microsoft-powered quantum computer to boost technological development in the Nordic ...

Novo Nordisk A/S (NYSE: NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company received a significant boost in its proposed $2.34 billion investment in a ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to controversial practices around the sale of compounded drugs.

On June 23, Novo Nordisk A/S (NYSE:NVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has given a positive opinion to update the Ozempic label.

Nevertheless, Novo Nordisk’s Ozempic and Rybelsus for diabetes and Wegovy for obesity are performing well, fueled by increasing demand.